SCHEMBL3799154

SCHEMBL3799154

O=S(=O)(NN1CCCCCC1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
ATM Q13315 1/20 0.50
ALDH1A1 P00352 5/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HTT P42858 2/20 0.49
PHGDH O43175 1/20 0.47
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
MMP13 P45452 1/20 0.45
KDM4E B2RXH2 2/20 0.45
THRB P10828 1/20 0.45
TSHR P16473 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
GAA P10253 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7115197 1.00 LMNA (0.53) LMNAATMALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL11538425 0.98 ATM (0.53) LMNAATMALDH1A1MEN1KMT2A
SCHEMBL2084284 0.98 ATM (0.51) LMNAATMALDH1A1MEN1KMT2A
SCHEMBL2227656 0.81 PHGDH (0.71) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL9189792 0.81 PHGDH (0.49) LMNAALDH1A1MEN1KMT2APHGDH
SCHEMBL6801446 0.81 MAPT (0.55) ALDH1A1MEN1KMT2AL3MBTL1PHGDH
SCHEMBL7131545 0.81 PHGDH (0.49) LMNAALDH1A1KMT2AHTTPHGDH
SCHEMBL7362762 0.81 HTR6 (0.55) ALDH1A1HTTPHGDHCA1CA2
SCHEMBL6797104 0.79 POLB (0.54) ALDH1A1MEN1KMT2AL3MBTL1PHGDH
SCHEMBL1490842 0.79 PHGDH (0.46) LMNAATMALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937181-B2 Benzenesulfonamide compounds and the use thereof PURDUE PHARMA L.P. (US) 2015-01-20 US disclosed
US-8765736-B2 Benzenesulfonamide compounds and the use thereof PURDUE PHARMA L.P. (US) 2014-07-01 US disclosed
US-20100311792-A1 Benzenesulfonamide Compounds and the Use Thereof PURDUE PHARMA L.P. 2010-12-09 US disclosed
US-20090306136-A1 Benzenesulfonamide Compounds and the Use Thereof PURDUE PHARMA L.P. 2009-12-10 US disclosed
WO-2009040659-A2 BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. (DE) 2009-04-02 WO disclosed
WO-2007118854-A1 BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311792-A1 Benzenesulfonamide Compounds and the Use Thereof CACNA1A, CACNA1E, CACNA1B LMNA 2734/4885ATM 4491/4885ALDH1A1 1954/4885
US-20090306136-A1 Benzenesulfonamide Compounds and the Use Thereof CACNA1A, CACNA1E, CACNA1B LMNA 2472/4885ATM 4370/4885ALDH1A1 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.